Aurobindo Pharma Ltd. Share Price

Aurobindo Pharma gets USFDA approval for Perampanel

Aurobindo Pharma Limited

Aurobindo Pharma gets USFDA nod for Perampanel

Aurobindo Pharma has received final USFDA approval to manufacture and market Perampanel Tablets in 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg strengths. Key highlights: - Estimated market size: $67 million for the 12 months ended August 2026. - Launch planned for Q3 FY27. - Manufacturing will be undertaken at Unit-IV of APL Healthcare, a wholly owned subsidiary. - Aurobindo Pharma now has 599 USFDA ANDA approvals, comprising 574 final and 25 tentative approvals. - Perampanel is indicated for the treatment of certain seizure disorders associated with epilepsy. Why it matters The approval expands Aurobindo Pharma's US generic portfolio and gives the company access to a market estimated at $67 million. The eventual revenue contribution will depend on launch timing, pricing, competition and market share. What to watch next Investors should track the Q3 FY27 launch, product uptake, pricing, competitive intensity and its contribution to US revenues. Analyst's view: The USFDA approval is a positive business development, while the actual earnings impact will depend on successful commercialisation and market penetration. Learning outcome: Investors should assess a pharma approval by considering market size, launch timeline, competition and potential market share rather than treating regulatory approval alone as an earnings estimate.

Aurobindo Pharma Hits 52-Week High After USFDA Nod

Aurobindo Pharma wins final USFDA approval

Aurobindo Pharma Ltd gets USFDA nod for $67 million drug

Aurobindo Pharma Ltd is in focus after receiving final USFDA approval for Perampanel Tablets in six strengths from 2 mg to 12 mg. The product has an estimated US market size of $67 million for the 12 months ended August 2026, according to IQVIA MAT data. The drug is bioequivalent and therapeutically equivalent to Fycompa Tablets, the reference product from Catalyst Pharmaceuticals. Aurobindo Pharma plans to manufacture the product through APL Healthcare and launch it in Q3 FY27. With this approval, the company’s total USFDA ANDA approvals have reached 599, including 574 final and 25 tentative approvals. Why it matters The approval strengthens Aurobindo Pharma’s US generics portfolio and provides another potential revenue opportunity. However, the $67 million market size is relatively small compared with the company’s overall business, so the immediate earnings impact may be limited. Technical view Aurobindo Pharma is trading around ₹1,681 on the daily chart. The broader trend remains positive as the stock is above the 50-day EMA at ₹1,645, 100-day SMA at ₹1,578 and 200-day SMA at ₹1,418. The key resistance zone is ₹1,695–₹1,705. A sustained breakout above ₹1,705 could open the way towards ₹1,750 and ₹1,800. Immediate support is at ₹1,660, followed by ₹1,645. A close below ₹1,645 could weaken the short-term trend. RSI is around 51, indicating neutral momentum, while ADX near 21 suggests moderate trend strength. MACD is showing some loss of short-term momentum. View: The USFDA approval is a positive fundamental trigger, but a sustained move above ₹1,705 would provide stronger technical confirmation. Disclosure: Neither I nor my family members hold any position in the mentioned stock at the time of publication.

Aurobindo Pharma receives USFDA approval